Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report - Summary - MDSpire

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

  • By

  • Carlen A. Yuen

  • Mahbod Jafarvand

  • David O. Kamson

  • Eleanor Chu

  • Jennifer E. Soun

  • William H. Yong

  • Frank P. Hsu

  • Hansen Bow

  • Michelle Zheng

  • Shyam M. Srinivas

  • June 11, 2026

  • 0 min

Share

Objective:

To present a case of a refractory meningioma patient treated with combination PRRT and octreotide, marking the first report of such treatment.

Approach:
    Key Findings:
    • The patient demonstrated stable disease with an 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria at 7 weeks post-treatment, indicating a potential positive response to the therapy.
    Interpretation:

    Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma, but further studies are needed to validate these findings.

    Limitations:
    • The study is based on a single case report, limiting generalizability, and the patient had a history of multiple treatments and comorbidities.
    Conclusion:

    This case suggests potential efficacy of combined PRRT and octreotide in refractory meningioma, warranting further investigation.

Original Source(s)

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

  • by Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, Eleanor Chu, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Hansen Bow, Michelle Zheng, Shyam M. Srinivas

  • June 11, 2026

Related Content

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

Clinical utility of an optoelectronic imaging tracing system for diagnosis of high-grade cervical lesions

Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer